NEW YORK (GenomeWeb News) – Judd Jessup has been named CEO of CombiMatrix, the firm said this week. Judd will take over the company's top position from interim CEO Mark McGowan, effective Aug. 23. Upon stepping down, McGowan will continue his duties as chairman of the firm's board of directors.
Jessup most recently was CEO of US Labs, a cancer diagnostic and genetic testing services lab. He also previously served as president of the Health Plans Division for FHP International, as well as the president of publicly traded HMO TakeCare.
According to a filing with the US Securities and Exchange Commission, Jessup will be paid a base salary of $420,000 per year and, subject to board approval, an annual performance bonus. Jessup was also granted a stock option to purchase 400,000 shares of CombiMatrix's common stock.
Sigma-Aldrich has named Magnus Borg VP and chief information officer for the firm. In the role, Borg will run the company's global information systems from its corporate headquarters in St. Louis. Borg has already spent more than 20 years with Sigma-Aldrich in IT management in the US and abroad, and he has worked as CIO for Ericsson North America.
The National Institutes of Health has appointed Lawrence Tabak to take over the job of principal deputy director for the departing Raynard Kington, who had held the position from 2003 to 2008. Kington, who also served as acting NIH Director from October 2008 to August 2009, has left his post at NIH to become president of Grinnell College.
Tabak was as director of the National Institute of Dental and Craniofacial Research since 2000, he was acting NIH deputy director for a time in 2009, and he most recently was acting director of the Division of Program Coordination, Planning, and Strategic Initiative.
Tabak's research has focused on biosynthesis and function of molecules that coat and protect the mucosal tissues of the human body.
"[Tabak's] outstanding service in numerous activities across the NIH and combination of skills and experience will help the NIH move forward in these revolutionary times for the biomedical sciences," NIH Director Francis Collins said in a statement.
The North Carolina Biotechnology Center has hired Peter Ginsberg to be VP of business and technology development. Ginsberg formerly was VP of business development and strategic planning at SurModics, and he has served as a consultant for biotech, pharmaceutical, and medical device clients. He also worked at Deephaven Capital Management on healthcare equity investments, he was a managing director and senior biotechnology analyst at Piper Jaffray, and he was a faculty member at the University of Minnesota's Carlson School of Management.
NanoInk this week appointed Oliver Yeh as general manager of sales for the Asia-Pacific region and Robert Marchmont as the general manager for Europe, the Middle East, and Africa. Yeh previously was the vice president and general manager at Veeco Instruments in Taiwan. Prior to that, he worked as the senior account sales manager for Lam Research, also in Taiwan.
Marchmont previously was the CEO at TotalLab in the UK. He was also the European business director for Protein Forest, and served as global marketing director for GE Healthcare's Life Science Division.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.